通过使用D-optimal设计专家®和体外表征方法优化和开发Ondansetron HCl纳米晶体
Zainab A Almusawi1, Eman B H Alkhedairy2
1Thiqar Health Directorate, Ministry of Health and Environment, Thiqar, Iraq.
Pakistan journal of pharmaceutical sciences
|February 28, 2026
概括
纳米晶技术通过提高其溶解率,提高了丹二 (ONH) 的生物可用性. 这项研究准备了ONH纳米晶体 (NCs) 用于潜在的舌下膜,旨在绕过第一通代谢.
科学领域:
- 制药技术 制药技术 制药技术
- 药物输送系统 药物输送系统
- 纳米技术纳米技术
背景情况:
- 纳米晶体技术提高了水溶性较差的药物的生物可用性.
- 昂丹塞特龙化 (ONH) 是一种抗药,具有较低的生物可用性 (约. 60%) 由于溶解性差和第一通代谢.
- ONH的溶解度取决于pH值,沉在pH值6以上.
研究的目的:
- 准备ONH纳米晶体 (ONH-NCs) 来增加溶解速度.
- 开发ONH-NCs作为子语言膜配方的初步步骤.
- 通过舌下药物输送绕过第一通代谢.
主要方法:
- 使用纳米沉方法制备的纳米晶体 (NCs).
- 通过D-最佳表面设计,变化的药物稳定剂比率,溶剂-抗溶剂比率,速率和稳定剂类型进行优化.
- 使用粒子大小分析,PDI,DSC,XRD,FTIR和FESEM进行表征.
主要成果:
- 获得的粒子大小 (PS) 从99-409nm和多分散度指数 (PDI) 从0.08-0.44.
- 使用了Soluplus®,Brij 35®和Kollidon VA 64®等稳定剂.
- 通过DSC/XRD证实了降低的结晶性;通过FTIR证实了药物稳定剂的兼容性;通过FESEM证实了形态.
结论:
- ONH的纳米结晶显示出更快的药物释放的潜力.
- 准备好的ONH-NCs可以提高ONH的生物可用性.
- 这项研究是对ONH的次语言电影开发的初步步骤.
相关概念视频
Factors Affecting Dissolution: Particle Size and Effective Surface Area
1.8K
Dissolution kinetics, an essential aspect of oral drug delivery, is significantly influenced by the drug's particle size. According to the Noyes-Whitney dissolution model, the dissolution rate correlates directly with the drug's surface area. The larger the surface area, the higher the drug's solubility in water, leading to a faster drug dissolution rate. Reducing particle size increases the effective surface area, enhancing the dissolution process. Micronization and nanosizing are...
1.8K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
744
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
744
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
209
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
209
In Vitro Drug Dissolution: Alternative Methods
296
Alternative drug dissolution methods include the rotating bottle, intrinsic dissolution test, peristalsis, and the Franz diffusion cell method. The rotating bottle method involves meticulously rotating tightly capped controlled-release beads in a temperature-controlled bath. Periodic decanting of samples allows for residue assay, followed by refilling with fresh medium and testing at various pH levels to emulate the gastrointestinal tract conditions.In contrast, the intrinsic dissolution test...
296
In Vitro Drug Dissolution: Compendial Testing Models I
383
Compendial dissolution methods are standardized procedures defined by pharmacopeias to evaluate the rate at which a drug dissolves in a specific medium. These methods ensure batch-to-batch consistency, enable quality control, and support the prediction of drug bioavailability. They are critical for both immediate and modified-release drug products.The apparatuses used for dissolution testing differ in their design and mechanical function, but all aim to simulate the physiological environment of...
383
Drug Delivery Systems: Different Types
107
Conventional oral drug products, termed immediate-release (IR) formulations, are engineered to promptly release their active pharmaceutical ingredient (API) upon ingestion, typically in tablets or capsules. This rapid release often results in swift drug absorption and consequent pharmacodynamic effects, although the timing and intensity can vary depending on the drug's properties. Prodrugs within these formulations require metabolic conversion to activate their pharmacodynamic effects,...
107


